首页 > 最新文献

Journal of Cardiovascular Surgery最新文献

英文 中文
Preliminary experience with new generation balloon expandable stent-graft in the treatment of innominate artery obstructive disease. 新一代球囊可扩张支架移植治疗无名动脉阻塞性疾病的初步体会。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2022-12-01 Epub Date: 2022-09-28 DOI: 10.23736/S0021-9509.22.12158-0
Michele Antonello, Andrea Xodo, Francesco Squizzato, Marco Zavatta, Carlo Maturi, Michele Piazza

Background: The aim of this study was to describe a single center preliminary experience with the use of a specific balloon expandable stent-graft for the treatment of innominate artery (IA) obstructive lesions.

Methods: We report our experience with four male patients treated with Gore Viabahn balloon (Gore Medical, Flagstaff, AZ, USA) expandable stent-graft for different types of IA stenosis: three patients were symptomatic for vertebrobasilar insufficiency, while one patient was asymptomatic for cerebrovascular symptoms. The stent grafts were deployed using retrograde (N.=2) or antegrade approach (N.=2), aiming to cover the entire lesions length and to slightly protrude into the aortic arch. Post-dilatation was performed with a compliant balloon. One patient presented a tandem lesion (IA and right internal carotid artery) and after the stenting of the IA he was treated also with a carotid artery stenting during the same procedure.

Results: Technical success was achieved in all patients. No perioperative or postoperative complications had been reported and the neurological disorders disappeared for the three symptomatic patients. After a mean clinical and radiological follow-up of 24±5 months, all the stents were patent and perfectly adapted to the vessels.

Conclusions: This preliminary clinical experience shows that the use of the Gore Viabahn balloon (Gore Medical) expandable stent-graft seems safe and feasible for the treatment of the IA obstructive lesions, also in presence of irregular plaques and hostile anatomies for an endovascular treatment. Larger experiences and long-term data are mandatory.

背景:本研究的目的是描述使用特定球囊可扩张支架移植治疗无名动脉(IA)阻塞性病变的单中心初步经验。方法:我们报告了4例男性患者使用Gore Viabahn球囊(Gore Medical, Flagstaff, AZ, USA)可扩张支架移植治疗不同类型IA狭窄的经验:3例患者有椎基底动脉功能不全症状,1例患者无脑血管症状。采用逆行(n =2)或顺行(n =2)入路放置支架,目的是覆盖整个病变长度并略微突出主动脉弓。扩张后用合规球囊进行。一名患者出现串联病变(IA和右颈内动脉),在IA支架植入术后,他在相同的手术过程中也接受了颈动脉支架植入术。结果:所有患者均获得技术成功。3例有症状患者均无围手术期及术后并发症,神经功能障碍消失。经过平均24±5个月的临床和影像学随访,所有支架均通畅,完全适应血管。结论:这一初步的临床经验表明,使用Gore Viabahn球囊(Gore Medical)可扩张支架移植物治疗IA阻塞性病变似乎是安全可行的,对于存在不规则斑块和不利解剖结构的血管内治疗也是如此。更大的经验和长期的数据是必须的。
{"title":"Preliminary experience with new generation balloon expandable stent-graft in the treatment of innominate artery obstructive disease.","authors":"Michele Antonello,&nbsp;Andrea Xodo,&nbsp;Francesco Squizzato,&nbsp;Marco Zavatta,&nbsp;Carlo Maturi,&nbsp;Michele Piazza","doi":"10.23736/S0021-9509.22.12158-0","DOIUrl":"https://doi.org/10.23736/S0021-9509.22.12158-0","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to describe a single center preliminary experience with the use of a specific balloon expandable stent-graft for the treatment of innominate artery (IA) obstructive lesions.</p><p><strong>Methods: </strong>We report our experience with four male patients treated with Gore Viabahn balloon (Gore Medical, Flagstaff, AZ, USA) expandable stent-graft for different types of IA stenosis: three patients were symptomatic for vertebrobasilar insufficiency, while one patient was asymptomatic for cerebrovascular symptoms. The stent grafts were deployed using retrograde (N.=2) or antegrade approach (N.=2), aiming to cover the entire lesions length and to slightly protrude into the aortic arch. Post-dilatation was performed with a compliant balloon. One patient presented a tandem lesion (IA and right internal carotid artery) and after the stenting of the IA he was treated also with a carotid artery stenting during the same procedure.</p><p><strong>Results: </strong>Technical success was achieved in all patients. No perioperative or postoperative complications had been reported and the neurological disorders disappeared for the three symptomatic patients. After a mean clinical and radiological follow-up of 24±5 months, all the stents were patent and perfectly adapted to the vessels.</p><p><strong>Conclusions: </strong>This preliminary clinical experience shows that the use of the Gore Viabahn balloon (Gore Medical) expandable stent-graft seems safe and feasible for the treatment of the IA obstructive lesions, also in presence of irregular plaques and hostile anatomies for an endovascular treatment. Larger experiences and long-term data are mandatory.</p>","PeriodicalId":50245,"journal":{"name":"Journal of Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40376701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TEVAR: future management based on today's scenarios. TEVAR:基于当前情景的未来管理。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2022-12-01 DOI: 10.23736/S0021-9509.22.12492-4
Mario E Rios Ramirez
{"title":"TEVAR: future management based on today's scenarios.","authors":"Mario E Rios Ramirez","doi":"10.23736/S0021-9509.22.12492-4","DOIUrl":"https://doi.org/10.23736/S0021-9509.22.12492-4","url":null,"abstract":"","PeriodicalId":50245,"journal":{"name":"Journal of Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10370267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Arterial thoracic outlet syndrome: a 30-year experience in a high-volume referral center. 动脉胸廓出口综合征:在一个大容量转诊中心的30年经验。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2022-12-01 Epub Date: 2022-09-14 DOI: 10.23736/S0021-9509.22.12224-X
Lazar B Davidovic, Petar Zlatanovic, Marko Dragas, Igor Koncar, Mihajlo Micic, David Matejevic

Background: The purpose of this study was to assess the clinical presentation and contemporary management of arterial thoracic outlet syndrome (TOS) in high-volume referral center.

Methods: We conducted a retrospective review of a prospectively maintained database of patients with TOS of any etiology between January 1st 1990 and 2021. Supra-, or combined supra-/infraclavicular approaches have been used for decompression/vascular reconstructions. The group was divided into two equal time periods: period 1 (1990-2006, N.=27) and period 2 (2006-2021, N.=36).

Results: Sixty-three consecutive patients underwent surgical treatment due to arterial TOS. Period 2 had more patients who were asymptomatic (N.=16, 44.4% vs. N.=0, 0%, P<0.001) and those presenting with critical hand ischemia (N.=12, 33.3% vs. N.=0, 0%, P=0.01), while acute limb ischemia was more common in period 1 (N.=16, 59.2% vs. N.=5, 13.9%, P<0.001). SA compression without lesion was more common in period 2 (N.=16, 44.4% vs. N.=0, 0%, P<0.001), while SA intimal damage with mural thrombus formation was more common in the period 1 (N.=12, 44.4% vs. N.=1, 2.7%, P<0.001). Decompression as an isolated procedure was performed in 25.4% (N.=16) of all asymptomatic patients, while combined decompressive and vascular procedure in 71.4% (N.=45) of patients. The most common postoperative complication was pneumothorax (N.=7, 11.1%).

Conclusions: The supraclavicular approach with its modifications provides adequate decompression and allows also repair or reconstruction of the SA, as well as complete additional revascularization of the upper extremity without the need for further patient repositioning. While treatment methods and early outcomes have not changed significantly over time, there has been a trend towards different clinical and SA pathomorphological presentation.

背景:本研究的目的是评估动脉胸廓出口综合征(TOS)在大容量转诊中心的临床表现和当代处理。方法:我们对1990年1月1日至2021年期间任何病因的TOS患者的前瞻性数据库进行了回顾性分析。锁骨上入路或锁骨上/锁骨下联合入路已被用于减压/血管重建。研究对象被分为两个相同的时间段:第1期(1990-2006年,27人)和第2期(2006-2021年,36人)。结果:63例患者连续因动脉性TOS接受手术治疗。第二期无症状患者较多(n = 16.44.4% vs. n = 0.0%)。结论:锁骨上入路及其改良提供了充分的减压,也允许SA修复或重建,以及上肢完全的额外血运重建术,而无需进一步的患者重新定位。虽然治疗方法和早期结果并没有随着时间的推移而发生显著变化,但临床和SA病理形态学表现的不同已经成为一种趋势。
{"title":"Arterial thoracic outlet syndrome: a 30-year experience in a high-volume referral center.","authors":"Lazar B Davidovic,&nbsp;Petar Zlatanovic,&nbsp;Marko Dragas,&nbsp;Igor Koncar,&nbsp;Mihajlo Micic,&nbsp;David Matejevic","doi":"10.23736/S0021-9509.22.12224-X","DOIUrl":"https://doi.org/10.23736/S0021-9509.22.12224-X","url":null,"abstract":"<p><strong>Background: </strong>The purpose of this study was to assess the clinical presentation and contemporary management of arterial thoracic outlet syndrome (TOS) in high-volume referral center.</p><p><strong>Methods: </strong>We conducted a retrospective review of a prospectively maintained database of patients with TOS of any etiology between January 1<sup>st</sup> 1990 and 2021. Supra-, or combined supra-/infraclavicular approaches have been used for decompression/vascular reconstructions. The group was divided into two equal time periods: period 1 (1990-2006, N.=27) and period 2 (2006-2021, N.=36).</p><p><strong>Results: </strong>Sixty-three consecutive patients underwent surgical treatment due to arterial TOS. Period 2 had more patients who were asymptomatic (N.=16, 44.4% vs. N.=0, 0%, P<0.001) and those presenting with critical hand ischemia (N.=12, 33.3% vs. N.=0, 0%, P=0.01), while acute limb ischemia was more common in period 1 (N.=16, 59.2% vs. N.=5, 13.9%, P<0.001). SA compression without lesion was more common in period 2 (N.=16, 44.4% vs. N.=0, 0%, P<0.001), while SA intimal damage with mural thrombus formation was more common in the period 1 (N.=12, 44.4% vs. N.=1, 2.7%, P<0.001). Decompression as an isolated procedure was performed in 25.4% (N.=16) of all asymptomatic patients, while combined decompressive and vascular procedure in 71.4% (N.=45) of patients. The most common postoperative complication was pneumothorax (N.=7, 11.1%).</p><p><strong>Conclusions: </strong>The supraclavicular approach with its modifications provides adequate decompression and allows also repair or reconstruction of the SA, as well as complete additional revascularization of the upper extremity without the need for further patient repositioning. While treatment methods and early outcomes have not changed significantly over time, there has been a trend towards different clinical and SA pathomorphological presentation.</p>","PeriodicalId":50245,"journal":{"name":"Journal of Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40359063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Propensity-matched comparison of right mini-thoracotomy versus median sternotomy for isolated mitral valve repair. 右小胸切开术与胸骨正中切开术在孤立二尖瓣修复中的倾向匹配比较。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2022-12-01 Epub Date: 2022-09-14 DOI: 10.23736/S0021-9509.22.12397-9
Sabet W Hashim, Sean R McMahon, Irena K Vaitkeviciute, Susan Collazo, Isabelle M Hashim, Deborah S Loya, Edmund T Takata, Jeff F Mather, Raymond G McKay

Background: A right mini-thoracotomy (RT) versus median sternotomy (MS) approach for isolated mitral valve (MV) repair has been associated with less postoperative morbidity, shorter hospital stay, and faster functional recovery, but with consistently longer cross-clamp time and higher operative costs.

Methods: We assessed the impact of a modified operative technique on outcomes in 158 RT versus 129 MS patients treated with myxomatous MV repair from 2016 through 2021. Propensity matching based upon the Society of Thoracic Surgeons Risk Score was used to compare 108 patients in each cohort.

Results: Propensity-matched RT patients had reductions in total ventilation time (P=0.025), postoperative atrial fibrillation (P=0.019), and hospital length of stay (P<0.001). RT and MS patients had similar cross-clamp times (66.4±13.7 vs 64.8±16.0 minutes, P=0.414), with less overall leaflet resection (32.4% vs 57.4%, P<0.001) and fewer Gore-Tex NeoChords implanted per patient (1.7±0.7 vs 2.1±1.0, P=0.028) in the RT group. The two cohorts did not differ with respect to 30-day major surgical complications. No patient died and there was no difference between the two groups with respect to freedom from re-operation (98.2% vs 98.2%, P=0.800) at a mean follow-up of 21.4±18.5 months. Direct total hospital costs were lower for the RT group (P=0.018), with reductions in postoperative charges offsetting increased operating room costs.

Conclusions: In this single-center study, the RT compared to the MS approach for myxomatous MV repair resulted in less postoperative morbidity and shorter hospital length of stay, with similar cross-clamp time, reduced total hospital costs, and comparable intermediate outcomes.

背景:相对于胸骨正中切开术(MS)入路,右侧小胸切开术(RT)对孤立二尖瓣(MV)的修复具有更低的术后发病率、更短的住院时间和更快的功能恢复,但始终需要更长的交叉夹持时间和更高的手术费用。方法:从2016年到2021年,我们评估了改良手术技术对158例RT和129例多发性硬化症患者接受黏液瘤MV修复治疗的结果的影响。基于胸外科学会风险评分的倾向匹配用于比较每个队列中的108例患者。结果:倾向匹配的RT患者总通气时间(P=0.025)、术后心房纤颤(P=0.019)和住院时间缩短(P)。结论:在这项单中心研究中,与MS方法相比,RT方法用于粘液瘤MV修复的术后发病率更低,住院时间更短,交叉夹持时间相似,总住院费用降低,中期结果相似。
{"title":"Propensity-matched comparison of right mini-thoracotomy versus median sternotomy for isolated mitral valve repair.","authors":"Sabet W Hashim,&nbsp;Sean R McMahon,&nbsp;Irena K Vaitkeviciute,&nbsp;Susan Collazo,&nbsp;Isabelle M Hashim,&nbsp;Deborah S Loya,&nbsp;Edmund T Takata,&nbsp;Jeff F Mather,&nbsp;Raymond G McKay","doi":"10.23736/S0021-9509.22.12397-9","DOIUrl":"https://doi.org/10.23736/S0021-9509.22.12397-9","url":null,"abstract":"<p><strong>Background: </strong>A right mini-thoracotomy (RT) versus median sternotomy (MS) approach for isolated mitral valve (MV) repair has been associated with less postoperative morbidity, shorter hospital stay, and faster functional recovery, but with consistently longer cross-clamp time and higher operative costs.</p><p><strong>Methods: </strong>We assessed the impact of a modified operative technique on outcomes in 158 RT versus 129 MS patients treated with myxomatous MV repair from 2016 through 2021. Propensity matching based upon the Society of Thoracic Surgeons Risk Score was used to compare 108 patients in each cohort.</p><p><strong>Results: </strong>Propensity-matched RT patients had reductions in total ventilation time (P=0.025), postoperative atrial fibrillation (P=0.019), and hospital length of stay (P<0.001). RT and MS patients had similar cross-clamp times (66.4±13.7 vs 64.8±16.0 minutes, P=0.414), with less overall leaflet resection (32.4% vs 57.4%, P<0.001) and fewer Gore-Tex NeoChords implanted per patient (1.7±0.7 vs 2.1±1.0, P=0.028) in the RT group. The two cohorts did not differ with respect to 30-day major surgical complications. No patient died and there was no difference between the two groups with respect to freedom from re-operation (98.2% vs 98.2%, P=0.800) at a mean follow-up of 21.4±18.5 months. Direct total hospital costs were lower for the RT group (P=0.018), with reductions in postoperative charges offsetting increased operating room costs.</p><p><strong>Conclusions: </strong>In this single-center study, the RT compared to the MS approach for myxomatous MV repair resulted in less postoperative morbidity and shorter hospital length of stay, with similar cross-clamp time, reduced total hospital costs, and comparable intermediate outcomes.</p>","PeriodicalId":50245,"journal":{"name":"Journal of Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40359064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Stroke and mortality rates after off-pump vs. pump-assisted/no-clamp coronary artery bypass grafting. 非泵与泵辅助/无钳冠状动脉旁路移植术后卒中和死亡率。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2022-12-01 Epub Date: 2022-09-28 DOI: 10.23736/S0021-9509.22.12337-2
George V Letsou, Fadi I Musfee, Qianzi Zhang, Gabriel Loor, Andrew D Lee

Background: Ascending aorta manipulation during on-pump coronary artery bypass grafting (CABG) surgery can release embolic matter and may cause stroke. Strategies for lowering the stroke rate associated with coronary artery bypass grafting surgery include off-pump surgery without cardiopulmonary bypass and pump-assisted surgery with minimal aortic manipulation (i.e., without aortic cross-clamping). We examined whether one approach is superior to the other in reducing stroke and perioperative mortality rates.

Methods: We reviewed consecutive elective, urgent, and emergency off-pump/no-bypass and pump-assisted/no-clamp coronary artery bypass grafting procedures performed by a single surgeon at our institution from June 2011 through October 2017.

Results: Of 570 patients analyzed, 395 (69.3%) underwent off-pump/no-bypass surgery, 43 (7.5%) underwent pump-assisted/no-clamp surgery, and 132 (23.2%) transitioned mid-procedure from off-pump/no-bypass to pump-assisted/no-clamp surgery. Patients who were >70 years old, were female, or had diabetes, cardiomegaly, or a history of myocardial infarction or congestive heart failure were more likely to undergo pump-assisted/no-clamp surgery or the combined technique. None of the pump-assisted/no-clamp patients had a stroke, versus 0.3% of the off-pump/no-bypass patients and 0.8% of the combination patients. Stroke and in-hospital mortality rates did not differ by technique.

Conclusions: A hybrid strategy incorporating off-pump, pump-assisted, and combined off-pump/pump-assisted techniques achieved very low stroke rates in patients undergoing coronary revascularization. Perioperative mortality was similar for all three techniques. Avoiding aortic clamping may be crucial for decreasing CABG-related stroke rates. Off-pump/no-bypass surgery had no significant advantage over the pump-assisted/no-clamp or combined techniques in reducing the stroke rate after coronary artery bypass grafting surgery.

背景:在无泵式冠状动脉旁路移植术(CABG)中操作升主动脉可以释放栓塞物质,并可能导致中风。降低与冠状动脉搭桥术相关的卒中发生率的策略包括无体外循环的无泵手术和最小主动脉操作的泵辅助手术(即无主动脉交叉夹紧)。我们研究了一种方法在降低卒中和围手术期死亡率方面是否优于另一种方法。方法:我们回顾了2011年6月至2017年10月在我院由一名外科医生进行的连续选择性、紧急、紧急无泵/无旁路和泵辅助/无钳冠状动脉旁路移植术。结果:在分析的570例患者中,395例(69.3%)接受了非泵/无旁路手术,43例(7.5%)接受了泵辅助/无夹钳手术,132例(23.2%)在手术中途从非泵/无旁路手术过渡到泵辅助/无夹钳手术。>70岁、女性、糖尿病、心脏肥大、有心肌梗死或充血性心力衰竭病史的患者更有可能接受泵辅助/无钳手术或联合技术。无泵辅助/无钳夹的患者没有发生卒中,而无泵辅助/无搭桥的患者为0.3%,联合使用的患者为0.8%。中风和住院死亡率没有因技术而异。结论:在接受冠状动脉血运重建术的患者中,结合非泵、泵辅助和非泵/泵辅助技术的混合策略可以实现非常低的卒中发生率。三种技术的围手术期死亡率相似。避免主动脉夹持可能是降低冠脉搭桥相关卒中发生率的关键。在降低冠状动脉搭桥术后卒中发生率方面,无泵/无旁路手术与泵辅助/无钳或联合技术相比没有显著优势。
{"title":"Stroke and mortality rates after off-pump vs. pump-assisted/no-clamp coronary artery bypass grafting.","authors":"George V Letsou,&nbsp;Fadi I Musfee,&nbsp;Qianzi Zhang,&nbsp;Gabriel Loor,&nbsp;Andrew D Lee","doi":"10.23736/S0021-9509.22.12337-2","DOIUrl":"https://doi.org/10.23736/S0021-9509.22.12337-2","url":null,"abstract":"<p><strong>Background: </strong>Ascending aorta manipulation during on-pump coronary artery bypass grafting (CABG) surgery can release embolic matter and may cause stroke. Strategies for lowering the stroke rate associated with coronary artery bypass grafting surgery include off-pump surgery without cardiopulmonary bypass and pump-assisted surgery with minimal aortic manipulation (i.e., without aortic cross-clamping). We examined whether one approach is superior to the other in reducing stroke and perioperative mortality rates.</p><p><strong>Methods: </strong>We reviewed consecutive elective, urgent, and emergency off-pump/no-bypass and pump-assisted/no-clamp coronary artery bypass grafting procedures performed by a single surgeon at our institution from June 2011 through October 2017.</p><p><strong>Results: </strong>Of 570 patients analyzed, 395 (69.3%) underwent off-pump/no-bypass surgery, 43 (7.5%) underwent pump-assisted/no-clamp surgery, and 132 (23.2%) transitioned mid-procedure from off-pump/no-bypass to pump-assisted/no-clamp surgery. Patients who were >70 years old, were female, or had diabetes, cardiomegaly, or a history of myocardial infarction or congestive heart failure were more likely to undergo pump-assisted/no-clamp surgery or the combined technique. None of the pump-assisted/no-clamp patients had a stroke, versus 0.3% of the off-pump/no-bypass patients and 0.8% of the combination patients. Stroke and in-hospital mortality rates did not differ by technique.</p><p><strong>Conclusions: </strong>A hybrid strategy incorporating off-pump, pump-assisted, and combined off-pump/pump-assisted techniques achieved very low stroke rates in patients undergoing coronary revascularization. Perioperative mortality was similar for all three techniques. Avoiding aortic clamping may be crucial for decreasing CABG-related stroke rates. Off-pump/no-bypass surgery had no significant advantage over the pump-assisted/no-clamp or combined techniques in reducing the stroke rate after coronary artery bypass grafting surgery.</p>","PeriodicalId":50245,"journal":{"name":"Journal of Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40376703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of fluid balance and blood transfusion during extracorporeal circulation on outcome for acute type A aortic dissection surgery. 体外循环中液体平衡和输血对急性A型主动脉夹层手术结果的影响。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2022-12-01 Epub Date: 2022-08-01 DOI: 10.23736/S0021-9509.22.12339-6
Jing Li, Andrea Stadlbauer, Anton Heller, Zhiyang Song, Walter Petermichl, Maik Foltan, Christof Schmid, Simon Schopka

Background: In thoracic aortic surgery, fluid replacement and blood transfusion during extracorporeal circulation (ECC) are associated with increased coagulopathy, elevated inflammatory response, and end-organ dysfunction. The optimal strategy has not been established in this regard. The aim of this study was to evaluate the effect of the fluid balance during ECC in thoracic aortic dissection surgery on outcome.

Methods: Between 2009 and 2020, 358 patients suffering from acute type A aortic dissection (ATAAD) underwent aortic surgery at our heart center. In-hospital mortality, major complications (postoperative stroke, respiratory failure, heart failure, acute renal failure), and follow-up mortality were assessed. Logistic regression analysis was used to identify whether fluid balance and blood transfusion during ECC were risk factors for occurring adverse events.

Results: The in-hospital mortality amounted to 20.4%. Major complications included temporary neurologic deficit in 13.4%, permanent neurologic deficit in 6.1%, acute renal failure in 32.7%, prolonged ventilation for respiratory failure in 17.9%, and acute heart failure in 10.9% of cases. At a mean of 42 months after discharge of 285 survivors, follow-up mortality was 13.3%. Multivariate analysis revealed major complications as well as the risk of in-hospital and follow-up mortality to increase with fluid balance and blood transfusion during ECC.

Conclusions: Fluid balance and blood transfusion during ECC present with predictive potential concerning the risk of postoperative adverse events.

背景:在胸主动脉手术中,体外循环(ECC)期间补液和输血与凝血功能障碍增加、炎症反应升高和终末器官功能障碍相关。这方面的最佳策略尚未确定。本研究的目的是评估胸主动脉夹层手术ECC期间体液平衡对预后的影响。方法:2009年至2020年,358例急性A型主动脉夹层(ATAAD)患者在我中心接受了主动脉手术。评估住院死亡率、主要并发症(术后中风、呼吸衰竭、心力衰竭、急性肾衰竭)和随访死亡率。采用Logistic回归分析确定ECC期间的体液平衡和输血是否是发生不良事件的危险因素。结果:住院死亡率为20.4%。主要并发症包括暂时性神经功能缺损(13.4%)、永久性神经功能缺损(6.1%)、急性肾功能衰竭(32.7%)、因呼吸衰竭延长通气时间(17.9%)和急性心力衰竭(10.9%)。285例幸存者出院后平均42个月,随访死亡率为13.3%。多因素分析显示,ECC期间体液平衡和输血增加了主要并发症、住院死亡率和随访死亡率的风险。结论:ECC期间的体液平衡和输血具有预测术后不良事件风险的潜力。
{"title":"Impact of fluid balance and blood transfusion during extracorporeal circulation on outcome for acute type A aortic dissection surgery.","authors":"Jing Li,&nbsp;Andrea Stadlbauer,&nbsp;Anton Heller,&nbsp;Zhiyang Song,&nbsp;Walter Petermichl,&nbsp;Maik Foltan,&nbsp;Christof Schmid,&nbsp;Simon Schopka","doi":"10.23736/S0021-9509.22.12339-6","DOIUrl":"https://doi.org/10.23736/S0021-9509.22.12339-6","url":null,"abstract":"<p><strong>Background: </strong>In thoracic aortic surgery, fluid replacement and blood transfusion during extracorporeal circulation (ECC) are associated with increased coagulopathy, elevated inflammatory response, and end-organ dysfunction. The optimal strategy has not been established in this regard. The aim of this study was to evaluate the effect of the fluid balance during ECC in thoracic aortic dissection surgery on outcome.</p><p><strong>Methods: </strong>Between 2009 and 2020, 358 patients suffering from acute type A aortic dissection (ATAAD) underwent aortic surgery at our heart center. In-hospital mortality, major complications (postoperative stroke, respiratory failure, heart failure, acute renal failure), and follow-up mortality were assessed. Logistic regression analysis was used to identify whether fluid balance and blood transfusion during ECC were risk factors for occurring adverse events.</p><p><strong>Results: </strong>The in-hospital mortality amounted to 20.4%. Major complications included temporary neurologic deficit in 13.4%, permanent neurologic deficit in 6.1%, acute renal failure in 32.7%, prolonged ventilation for respiratory failure in 17.9%, and acute heart failure in 10.9% of cases. At a mean of 42 months after discharge of 285 survivors, follow-up mortality was 13.3%. Multivariate analysis revealed major complications as well as the risk of in-hospital and follow-up mortality to increase with fluid balance and blood transfusion during ECC.</p><p><strong>Conclusions: </strong>Fluid balance and blood transfusion during ECC present with predictive potential concerning the risk of postoperative adverse events.</p>","PeriodicalId":50245,"journal":{"name":"Journal of Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40661283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dealing with malignancy involving the inferior vena cava in the 21st century. 21世纪下腔静脉恶性肿瘤的处理。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2022-12-01 Epub Date: 2022-10-14 DOI: 10.23736/S0021-9509.22.12408-0
Marco Baia, David N Naumann, Chee S Wong, Fahad Mahmood, Alessandro Parente, Daniele Bissacco, Max Almond, Samuel J Ford, Fabio Tirotta, Anant Desai

Introduction: Malignancies involving the inferior vena cava (IVC) have historically been considered not amendable to surgery. More recently, involvement of the IVC by neoplastic processes in the kidney, liver or in the retroperitoneum can be managed successfully.

Evidence acquisition: In this systematic review we summarize the current evidence regarding the surgical management of the IVC in cases of involvement in neoplastic processes. Current literature was searched, and studies selected on the base of the PRISMA guidelines. Evidence was synthesized in narrative form due to heterogeneity of studies.

Evidence synthesis: Renal cell carcinoma accounts for the greatest proportion of studied patients and can be managed with partial or complete vascular exclusion of the IVC, thrombectomy and direct closure or patch repair with good oncological prognosis. Hepatic malignancies or metastases may involve the IVC, and the joint expertise of hepatobiliary and vascular surgeons has developed various strategies, according to the location of tumor and the need to perform a complete vascular exclusion above the hepatic veins. In retroperitoneal lymph node dissection, the IVC can be excised en-block to guarantee better oncological margins. Also, in retroperitoneal sarcomas not arising from the IVC a vascular substitution may be required to improve the overall survival by clearing all the neoplastic cells in the retroperitoneum. Leiomyoma can have a challenging presentation with involvement of the IVC requiring either thrombectomy, partial or complete substitution, with good oncological outcomes.

Conclusions: A multidisciplinary approach with specialist expertise is required when dealing with IVC involvement in surgical oncology. Multiple techniques and strategies are required to deliver the most efficient care and achieve the best possible overall survival. The main aim of these procedures must be the complete clearance of all neoplastic cells and achievement of a safe margin according to the perioperative treatment strategy.

简介:恶性肿瘤累及下腔静脉(IVC)历来被认为不能通过手术治疗。最近,肿瘤进程累及下腔静脉在肾脏、肝脏或腹膜后可以成功地处理。证据获取:在这篇系统综述中,我们总结了目前关于下腔静脉肿瘤病变的外科治疗的证据。检索当前文献,并根据PRISMA指南选择研究。由于研究的异质性,证据以叙述形式综合。证据综合:肾细胞癌占研究患者的最大比例,可以通过部分或完全排除下腔静脉血管、取栓、直接闭合或补片修复来治疗,肿瘤预后良好。肝脏恶性肿瘤或转移可能涉及下腔静脉,肝胆和血管外科医生的联合专业知识已经制定了各种策略,根据肿瘤的位置和需要进行肝静脉以上的完全血管排除。在腹膜后淋巴结清扫,下腔静脉可以被切除,以保证更好的肿瘤边界。此外,对于不是由下腔静脉引起的腹膜后肉瘤,可能需要血管替代,通过清除腹膜后所有的肿瘤细胞来提高总生存率。平滑肌瘤具有挑战性的表现,涉及下腔静脉,需要取栓,部分或完全替代,肿瘤预后良好。结论:在外科肿瘤学中处理下腔静脉病变时,需要多学科的专业知识。需要多种技术和策略来提供最有效的护理并实现最佳的总体生存。这些手术的主要目的必须是完全清除所有肿瘤细胞,并根据围手术期治疗策略达到安全边缘。
{"title":"Dealing with malignancy involving the inferior vena cava in the 21st century.","authors":"Marco Baia,&nbsp;David N Naumann,&nbsp;Chee S Wong,&nbsp;Fahad Mahmood,&nbsp;Alessandro Parente,&nbsp;Daniele Bissacco,&nbsp;Max Almond,&nbsp;Samuel J Ford,&nbsp;Fabio Tirotta,&nbsp;Anant Desai","doi":"10.23736/S0021-9509.22.12408-0","DOIUrl":"https://doi.org/10.23736/S0021-9509.22.12408-0","url":null,"abstract":"<p><strong>Introduction: </strong>Malignancies involving the inferior vena cava (IVC) have historically been considered not amendable to surgery. More recently, involvement of the IVC by neoplastic processes in the kidney, liver or in the retroperitoneum can be managed successfully.</p><p><strong>Evidence acquisition: </strong>In this systematic review we summarize the current evidence regarding the surgical management of the IVC in cases of involvement in neoplastic processes. Current literature was searched, and studies selected on the base of the PRISMA guidelines. Evidence was synthesized in narrative form due to heterogeneity of studies.</p><p><strong>Evidence synthesis: </strong>Renal cell carcinoma accounts for the greatest proportion of studied patients and can be managed with partial or complete vascular exclusion of the IVC, thrombectomy and direct closure or patch repair with good oncological prognosis. Hepatic malignancies or metastases may involve the IVC, and the joint expertise of hepatobiliary and vascular surgeons has developed various strategies, according to the location of tumor and the need to perform a complete vascular exclusion above the hepatic veins. In retroperitoneal lymph node dissection, the IVC can be excised en-block to guarantee better oncological margins. Also, in retroperitoneal sarcomas not arising from the IVC a vascular substitution may be required to improve the overall survival by clearing all the neoplastic cells in the retroperitoneum. Leiomyoma can have a challenging presentation with involvement of the IVC requiring either thrombectomy, partial or complete substitution, with good oncological outcomes.</p><p><strong>Conclusions: </strong>A multidisciplinary approach with specialist expertise is required when dealing with IVC involvement in surgical oncology. Multiple techniques and strategies are required to deliver the most efficient care and achieve the best possible overall survival. The main aim of these procedures must be the complete clearance of all neoplastic cells and achievement of a safe margin according to the perioperative treatment strategy.</p>","PeriodicalId":50245,"journal":{"name":"Journal of Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33511063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary malignancy of the inferior vena cava, a review of surgical treatments and outcomes. 原发性下腔静脉恶性肿瘤的外科治疗和结果综述。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2022-12-01 Epub Date: 2022-10-14 DOI: 10.23736/S0021-9509.22.12418-3
Alessandra Borghi, Alessandra Scotto DI Uccio, Alessandro Gronchi

Introduction: Primary malignancies of the inferior vena cava comprise a heterogeneous group of histologic types that generally have a poor prognosis. Their rarity limits the data available in literature. There is no doubt that surgery is the mainstay treatment, but several questions about the best surgical strategy and multidisciplinary approach remain. The present review covers the surgical technique including the various reconstructive modalities and the available evidence about treatments and outcomes.

Evidence acquisition: From literature research, we identified 15 case series of patients with primary inferior vena cava tumors, who underwent surgery from 2000 onwards. Details on resection and reconstruction, focusing on both oncologic and surgical issues, were analyzed and summarized.

Evidence synthesis: Inferior vena cava malignancies can be either primary or secondary. The main primary tumor is leiomyosarcoma, while retroperitoneal liposarcomas and renal carcinomas are the main causes of secondary invasion. The outcomes of primary inferior vena cava leiomyosarcoma are linked to its metastatic risk. However, long-term survivors do exist. The factors that determine the surgical strategy include extent of the disease, which segment is involved, additional organ resection needed, presence of collateral venous circulation. After a partial resection, the wall defect can be repaired primarily or by patch interposition. After a circumferential resection, the first decision is whether to reconstruct the vascular continuity. There are several options, including prosthetic (polytetrafluoroethylene and Dacron) or biological materials (from autologous venous grafts to cryopreserved aortic grafts).

Conclusions: Tumors involving inferior vena cava are rare and challenging. A specific expertise is required to select the most appropriate surgical resection and reconstruction for the single patients in order to maximize the chance of cure alongside the quality of life.

下腔静脉的原发性恶性肿瘤包括一组不同的组织学类型,通常预后较差。它们的稀有性限制了文献资料的可用性。毫无疑问,手术是主要的治疗方法,但关于最佳手术策略和多学科方法的几个问题仍然存在。目前的回顾涵盖了外科技术,包括各种重建模式和现有的证据,治疗和结果。证据获取:从文献研究中,我们确定了15例自2000年以来接受手术治疗的原发性下腔静脉肿瘤患者。详细的切除和重建,重点是肿瘤和外科问题,分析和总结。证据综合:下腔静脉恶性肿瘤可为原发性或继发性。主要原发肿瘤为平滑肌肉瘤,腹膜后脂肪肉瘤和肾癌是继发侵袭的主要原因。原发性下腔静脉平滑肌肉瘤的预后与其转移风险有关。然而,长期的幸存者确实存在。决定手术策略的因素包括疾病的范围,涉及哪一节段,需要额外的器官切除,侧静脉循环的存在。局部切除后,可以主要修复或补片介入修复。围手术切除后,首先要考虑的是是否重建血管的连续性。有几种选择,包括假体(聚四氟乙烯和涤纶)或生物材料(从自体静脉移植到低温保存的主动脉移植)。结论:累及下腔静脉的肿瘤是罕见且具有挑战性的。为单个患者选择最合适的手术切除和重建,以最大限度地提高治愈机会和生活质量,需要特定的专业知识。
{"title":"Primary malignancy of the inferior vena cava, a review of surgical treatments and outcomes.","authors":"Alessandra Borghi,&nbsp;Alessandra Scotto DI Uccio,&nbsp;Alessandro Gronchi","doi":"10.23736/S0021-9509.22.12418-3","DOIUrl":"https://doi.org/10.23736/S0021-9509.22.12418-3","url":null,"abstract":"<p><strong>Introduction: </strong>Primary malignancies of the inferior vena cava comprise a heterogeneous group of histologic types that generally have a poor prognosis. Their rarity limits the data available in literature. There is no doubt that surgery is the mainstay treatment, but several questions about the best surgical strategy and multidisciplinary approach remain. The present review covers the surgical technique including the various reconstructive modalities and the available evidence about treatments and outcomes.</p><p><strong>Evidence acquisition: </strong>From literature research, we identified 15 case series of patients with primary inferior vena cava tumors, who underwent surgery from 2000 onwards. Details on resection and reconstruction, focusing on both oncologic and surgical issues, were analyzed and summarized.</p><p><strong>Evidence synthesis: </strong>Inferior vena cava malignancies can be either primary or secondary. The main primary tumor is leiomyosarcoma, while retroperitoneal liposarcomas and renal carcinomas are the main causes of secondary invasion. The outcomes of primary inferior vena cava leiomyosarcoma are linked to its metastatic risk. However, long-term survivors do exist. The factors that determine the surgical strategy include extent of the disease, which segment is involved, additional organ resection needed, presence of collateral venous circulation. After a partial resection, the wall defect can be repaired primarily or by patch interposition. After a circumferential resection, the first decision is whether to reconstruct the vascular continuity. There are several options, including prosthetic (polytetrafluoroethylene and Dacron) or biological materials (from autologous venous grafts to cryopreserved aortic grafts).</p><p><strong>Conclusions: </strong>Tumors involving inferior vena cava are rare and challenging. A specific expertise is required to select the most appropriate surgical resection and reconstruction for the single patients in order to maximize the chance of cure alongside the quality of life.</p>","PeriodicalId":50245,"journal":{"name":"Journal of Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33511064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Trends and treatments in vena cava disease: advancements, possibilities and perspectives. 腔静脉疾病的趋势和治疗:进展、可能性和前景。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2022-12-01 DOI: 10.23736/S0021-9509.22.12520-6
Daniele Bissacco, Renato Casana
{"title":"Trends and treatments in vena cava disease: advancements, possibilities and perspectives.","authors":"Daniele Bissacco,&nbsp;Renato Casana","doi":"10.23736/S0021-9509.22.12520-6","DOIUrl":"https://doi.org/10.23736/S0021-9509.22.12520-6","url":null,"abstract":"","PeriodicalId":50245,"journal":{"name":"Journal of Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10370266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interventions for superior vena cava syndrome. 上腔静脉综合征的干预措施。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2022-12-01 DOI: 10.23736/S0021-9509.22.12448-1
Indrani Sen, Manju Kalra, Peter Gloviczki

Superior vena cava (SVC) syndrome refers to the clinical manifestations of cerebral venous hypertension secondary to obstruction of the SVC and/or the innominate veins. The most common cause of SVC syndrome is malignancy like small cell lung cancer and non-Hodgkin lymphoma, but there is an increasing trend of benign etiologies secondary to thrombosis due to central lines/ pacemakers or mediastinal fibrosis. Supportive measures include head elevation, diuresis, supplemental oxygen, and steroids. Thrombolysis with or without endovenous stenting is required emergently in those with airway compromise or symptoms secondary to cerebral edema. Definitive treatment in those with malignancy is multidisciplinary; this requires radiotherapy, chemotherapy, SVC stenting, oncologic surgery and SVC bypass or reconstruction. Endovascular treatment is the primary modality for palliation in malignancy and in those with benign etiology. Surgery is reserved for those who have failed or are unsuitable for endovascular treatment. In patients with benign disease endovenous stenting and open surgery provide excellent symptom relief and are safe and effective.

上腔静脉(SVC)综合征是指继发于上腔静脉和/或无名静脉阻塞的脑静脉高压的临床表现。SVC综合征最常见的病因是恶性肿瘤,如小细胞肺癌和非霍奇金淋巴瘤,但由于中央线/起搏器或纵隔纤维化而继发的良性病因越来越多。支持措施包括抬高头部、利尿、补充氧气和类固醇。对于气道受损或继发于脑水肿的患者,溶栓伴或不伴静脉内支架植入术是紧急需要的。恶性肿瘤的最终治疗是多学科的;这需要放疗、化疗、SVC支架置入术、肿瘤手术和SVC搭桥或重建。血管内治疗是缓解恶性肿瘤和那些良性病因的主要方式。手术是为那些失败或不适合血管内治疗的患者保留的。对于患有良性疾病的患者,静脉内支架置入和开放手术提供了良好的症状缓解,并且安全有效。
{"title":"Interventions for superior vena cava syndrome.","authors":"Indrani Sen,&nbsp;Manju Kalra,&nbsp;Peter Gloviczki","doi":"10.23736/S0021-9509.22.12448-1","DOIUrl":"https://doi.org/10.23736/S0021-9509.22.12448-1","url":null,"abstract":"<p><p>Superior vena cava (SVC) syndrome refers to the clinical manifestations of cerebral venous hypertension secondary to obstruction of the SVC and/or the innominate veins. The most common cause of SVC syndrome is malignancy like small cell lung cancer and non-Hodgkin lymphoma, but there is an increasing trend of benign etiologies secondary to thrombosis due to central lines/ pacemakers or mediastinal fibrosis. Supportive measures include head elevation, diuresis, supplemental oxygen, and steroids. Thrombolysis with or without endovenous stenting is required emergently in those with airway compromise or symptoms secondary to cerebral edema. Definitive treatment in those with malignancy is multidisciplinary; this requires radiotherapy, chemotherapy, SVC stenting, oncologic surgery and SVC bypass or reconstruction. Endovascular treatment is the primary modality for palliation in malignancy and in those with benign etiology. Surgery is reserved for those who have failed or are unsuitable for endovascular treatment. In patients with benign disease endovenous stenting and open surgery provide excellent symptom relief and are safe and effective.</p>","PeriodicalId":50245,"journal":{"name":"Journal of Cardiovascular Surgery","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35209928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
期刊
Journal of Cardiovascular Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1